TYRA

20.1201.98%
JS

Jake Simson

Independent Director

Dr. Jake Simson, Ph.D. is Independent Director of Septerna, Inc. from June 2023. Dr. Simson is Independent Non-Employee Director of Parabilis Medicines, Inc. from January 2026. Dr. Simson is Director of Vivace Therapeutics, Inc. from March 2025. He serves as Director at Outpace Bio, Inc. He has been an Independent Director of Tyra Biosciences, Inc. since January 2020, DICE Therapeutics, Inc. since December 2020 (formerly DiCE Molecules Holdings, LLC). He has been Director at DiCE Molecules SV, Inc. since December 31, 2020, Bicara Therapeutics Inc. since March 2023 and Cedilla Therapeutics, Inc. since October 2021. He currently serves as Director of Convergent Therapeutics Inc. Dr. Simson serves as a Non-Executive Director at Xenikos B.V. He serves as a Director at AavantiBio and Xenikos, B.V. He has been a Partner at RA Capital Management, L.P. since December 2020. Previously, Dr. Simson served as an Associate, Analyst and Principal at RA Capital Management, LLC from July 2013 to December 2020. Previously, Dr. Simson covered solid tumor oncology landscapes. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. He has been an Independent Director of Janux Therapeutics, Inc. since March 3, 2021. Dr. Simson holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University.

Positions